The MD Anderson complaint against Patrick Soon-Shiong and his business entities, filed Nov. 30, 2016, in the U.S. District Court for the Southern District of Texas, argues that the controversial billionaire's use of the moonshot trademark created confusion that affected both MD Anderson and the White House initiative headed by then Vice President Joe Biden.
Overnight, cancer pharmaceuticals billionaire Patrick Soon-Shiong stopped using the trademark “MoonShot” to describe his health initiatives, opting instead to use the less grabby, but equally ambitious, name “cancer breakthroughs.”
About a year ago, Sandip Patel, a young doctor who had just joined the faculty at University of California San Diego Moores Cancer Center, stopped by to see his mentor, Razelle Kurzrock, chair of the SWOG Early Therapeutics and Rare Cancers Committee.
Baptist Health South Florida earlier this week opened the Miami Cancer Institute.
LUNGevity and CancerCare announced the launch of the LUNGevity Lung Cancer HELPLine, a free phone service through which a team of oncology social workers will be available to address the emotional, practical, and information needs of people diagnosed with lung cancer, their families, and caregivers.
Highlighting immunotherapy research from 2016, a white paper from the Institute for Clinical Immuno-Oncology founded by the Association of Community Cancer Centers isolated emerging policy issues and challenges that may impact the future of immune-oncology in practice.
Vinay Prasad, an assistant professor of medicine in the OHSU School of Medicine and member of the OHSU Knight Cancer Institute, noticed potential financial conflicts of interest among physicians on Twitter and realized the issue had never been formally studied.
FDA approved the drug Imbruvica (imbrutinib) for the treatment of patients with relapsed/refractory marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20-based therapy.
Merck KGaA, Darmstadt, Germany, announced a collaboration and licensing agreement with Domain Therapeutics, Strasbourg, France, to explore the potential of adenosine inhibition in the development of novel immuno-oncology agents.
MD Anderson Cancer Center lost $58 million during the month of December 2016.
